Filtered By:
Condition: Pregnancy
Infectious Disease: SARS
This page shows you your search results in order of date.
Order by Relevance | Date
Total 24 results found since Jan 2013.
Why It Took So Long to Finally Get an RSV Vaccine
Respiratory syncytial virus (RSV) can dangerously compromise breathing, especially for infants and the elderly. But there has been no vaccine to prevent it—until today. On May 3, the U.S. Food and Drug Administration (FDA) approved the first vaccine against RSV, from GlaxoSmithKline (GSK), to prevent respiratory disease in people ages 60 and older. The Centers for Disease Control’s vaccine committee will make formal recommendations in June about who should receive the vaccine, but GSK says it currently has enough doses to vaccinate eligible people beginning this fall.
In studies involving 25,000 people that GSK...
Source: TIME: Health - May 3, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news
Local Immune Responses in Placentas of Women with COVID-19 SARS Complicated Pregnancy Increase with Each Trimester
This study assesses the features of local immune responses in placentas of women with COVID-19.
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Galyna Yeryomenko, Lawrence DuBuske, Myhaylo Myrosnuchenko Source Type: research
‘Extremely satisfying’: Scientist’s insight powers new RSV vaccine for infants
Barney Graham, a former scientist at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), was thrilled yesterday when
Pfizer announced encouraging results
from an experimental vaccine that could protect against a major childhood killer. In a press release, the company said immunizing pregnant women
*
with its vaccine against respiratory syncytial virus (RSV) protected their babies from severe disease for 6 months. If the full results of its clinical trial bear out that promise, the vaccine could spare millions of infants worldwide from RSV-related hospitalization, reduce lasting lung damage f...
Source: Science of Aging Knowledge Environment - November 2, 2022 Category: Geriatrics Source Type: research
Antibody weapon against malaria shows promise in Africa
A new way to prevent malaria that showed promise in 9 U.S. volunteers deliberately exposed to parasite-laden mosquitoes last year has now shown its mettle in a real-world situation in Africa. A study published today in the
New England Journal of Medicine
showed that
a single dose
of lab-produced monoclonal antibodies can protect recipients from infection for up to 6 months during Mali’s intense malaria season.
Monoclonal antibodies are expensive to produce and can be cumbersome to administer if they are infused straight into the bloodstream. That makes some researchers skeptical that the new ones to thwa...
Source: ScienceNOW - November 1, 2022 Category: Science Source Type: news
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
Lancet Respir Med. 2022 May 23:S2213-2600(22)00088-1. doi: 10.1016/S2213-2600(22)00088-1. Online ahead of print.ABSTRACTBACKGROUND: Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to mechanical ventilation or death in hospitalised patients with COVID-19.METHODS: In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites)...
Source: Respiratory Care - May 26, 2022 Category: Respiratory Medicine Authors: Cameron R Wolfe Kay M Tomashek Thomas F Patterson Carlos A Gomez Vincent C Marconi Mamta K Jain Otto O Yang Catharine I Paules Guillermo M Ruiz Palacios Robert Grossberg Michelle S Harkins Richard A Mularski Nathaniel Erdmann Uriel Sandkovsky Eyad Almasri Source Type: research
10 Black Americans Who Have Led COVID-19 Response
By The Editorial Team,
IntraHealth InternationalFebruary 22, 2022Meet 10 Black American leaders who are shaping local and national COVID-19 response. These scientists, researchers, policymakers, teachers, and more have seen first-hand how the pandemic exacerbates racial disparities in health. In the US, Black Americans have died from COVID-19 at1.4 times the rate of white people.Today we’re highlighting these leaders as they work to protect their communities and inform our global response to the pandemic.Christopher BarnesAssistant professor, Department of Biology at Stanford UniversityWhen COVID-19 began, Bar...
Source: IntraHealth International - February 17, 2022 Category: International Medicine & Public Health Authors: kseaton Tags: COVID-19 Health Workers Source Type: news
Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
NEW BRUNSWICK, N.J., December 15, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company’s COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson & Johnson COVID-19 vaccine, and as a ‘mix and match’ booster following primary vaccination with an approved two-shot mRNA COVID-19 vaccine regimen (known as heterologous boosting). “We are pleased with today’s Positiv...
Source: Johnson and Johnson - December 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Sex and gender in asthma
Asthma is a heterogenous disease, and its prevalence and severity are different in males versus females through various ages. As children, boys have an increased prevalence of asthma. As adults, women have an increased prevalence and severity of asthma. Sex hormones, genetic and epigenetic variations, social and environmental factors, and responses to asthma therapeutics are important factors in the sex differences observed in asthma incidence, prevalence and severity. For women, fluctuations in sex hormone levels during puberty, the menstrual cycle and pregnancy are associated with asthma pathogenesis. Further, sex differ...
Source: European Respiratory Review - November 17, 2021 Category: Respiratory Medicine Authors: Chowdhury, N. U., Guntur, V. P., Newcomb, D. C., Wechsler, M. E. Tags: Asthma and allergy Sex and gender in lung disease Source Type: research
An immunologist's perspective on anti-COVID-19 vaccines
Purpose of review
Antisevere acute respiratory syndrome-corona virus 2 (SARS-CoV-2) vaccines may provide prompt, effective, and safe solution for the COVID-19 pandemic. Several vaccine candidates have been evaluated in randomized clinical trials (RCTs). Furthermore, data from observational studies mimicking real-life practice and studies on specific groups, such as pregnant women or immunocompromised patients who were excluded from RCTs, are currently available. The main aim of the review is to summarize and provide an immunologist's view on mechanism of action, efficacy and safety, and future challenges in vaccination...
Source: Current Opinion in Allergy and Clinical Immunology - November 8, 2021 Category: Allergy & Immunology Tags: PRIMARY IMMUNE DEFICIENCY DISEASE: Edited by M. Teresa de la Morena and Stephen Jolles Source Type: research
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety
AbstractTo date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit –risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or p revious SARS...
Source: Drug Safety - November 5, 2021 Category: Drugs & Pharmacology Source Type: research
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial
Lancet Respir Med. 2021 Oct 18:S2213-2600(21)00384-2. doi: 10.1016/S2213-2600(21)00384-2. Online ahead of print.ABSTRACTBACKGROUND: Functional impairment of interferon, a natural antiviral component of the immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to compare the efficacy of interferon beta-1a in combination with remdesivir compared with remdesivir alone in hospitalised patients with COVID-19.METHODS: We did a double-blind, randomised, placebo-controlled trial at 63 hospitals across five countries (Japan, Mexico, Singapore, South Korea, and the USA). Eligible patients were hospita...
Source: Respiratory Care - October 21, 2021 Category: Respiratory Medicine Authors: Andre C Kalil Aneesh K Mehta Thomas F Patterson Nathaniel Erdmann Carlos A Gomez Mamta K Jain Cameron R Wolfe Guillermo M Ruiz-Palacios Susan Kline Justino Regalado Pineda Anne F Luetkemeyer Michelle S Harkins Patrick E H Jackson Nicole M Iovine Victor F Source Type: research
Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
This study compared approximately 390,000 people who received the Company’s single-shot COVID-19 vaccine versus approximately 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code, and comorbidities and predictors for COVID-19 infection severity.This study is a longitudinal cohort design, using robust propensity matching methods to create a comparator cohort to assess real-world VE. All analyses were performed using the Aetion Evidence Platform, which is a scientifically validated software that is also used by regulators, payers, and health technology assessment bodies to assess the safety, eff...
Source: Johnson and Johnson - September 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Maternal COVID-19, vaccination safety in pregnancy, and evidence of protective immunity
Over the past 18 months, the world has seen the largest pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of June 28, 2021, the Centers for Disease Control and Prevention (CDC) reported 98,948 cases of coronavirus disease 2019 (COVID-19) infection in pregnancy and 109 related maternal deaths in the United States alone.1 As the pandemic continues to evolve, the rapid and overwhelming increase in available evidence on the impact in pregnancy has resulted in studies of varying degrees of bias and quality.
Source: Journal of Allergy and Clinical Immunology - July 24, 2021 Category: Allergy & Immunology Authors: Amelie Pham, David M. Aronoff, Jennifer L. Thompson Tags: COVID-19 Source Type: research
